Nicotine Addiction
Understanding tobacco and vape dependence, withdrawal, mental health impact, and evidence-based residential treatment at Phuket Island Rehab.
Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician and Addiction Medicine Specialist, Phuket Island Rehab.
Nicotine is the principal addictive component of tobacco products and of most vape and pouch products. The drug acts at nicotinic acetylcholine receptors in the brain, drives dopamine release in the reward system, and produces both physical dependence and a recognisable pattern of compulsive use that persists in the face of clear health harms. Most people who smoke or vape daily are addicted to nicotine, and the dependence is widely regarded as among the strongest of any drug of misuse. Common nicotine withdrawal symptoms include irritability, anxiety, cravings, low mood, restlessness, sleep disruption, and difficulty concentrating, and the symptoms peak in the first week of stopping. At Phuket Island Rehab, our clinical team treats nicotine addiction as a serious dependence in its own right and routinely alongside alcohol use disorder and other substance use disorders, with structured behavioural support, evidence-based pharmacotherapy, and the residential setting that gives patients a real chance of long-term recovery.
What is nicotine addiction?
Nicotine addiction is a chronic relapsing disorder characterised by compulsive use of nicotine-containing products despite clear evidence of harm. The condition is recognised in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders as tobacco use disorder, with criteria similar to other substance use disorders including tolerance, withdrawal, failed attempts to quit, and continued use despite physical or psychological consequences. The World Health Organization classifies nicotine dependence as one of the leading preventable causes of disease and premature death globally, responsible for over eight million deaths per year through tobacco-related cancer, cardiovascular disease, and respiratory illness.
Most people who smoke or vape daily meet criteria for nicotine dependence within months of starting regular use. The drug is delivered to the brain within seconds by inhaled smoke or vapour, with a sharp peak of nicotine concentration that produces a brief but reliable pleasurable effect, and the body learns to repeat the behaviour many times per day. By the time a regular smoker is consuming a pack a day, the brain has experienced 60,000 to 80,000 reinforced nicotine exposures in a year, far more than any other addictive drug delivers in the same period. This explains both why nicotine dependence is so consistent across regular users and why it is so resistant to casual attempts to stop.
How nicotine works in the brain
Nicotine acts at nicotinic acetylcholine receptors, a family of ligand-gated ion channels distributed throughout the central nervous system, the autonomic nervous system, and neuromuscular junctions. Binding to the alpha-4-beta-2 receptor subtype in the ventral tegmental area drives release of dopamine in the nucleus accumbens, the same reward signal that underlies addiction to all major drugs of misuse. The dopamine signal produces a transient pleasurable effect, reinforces the act of inhaling, and over weeks and months drives the circuit-level changes that underpin sustained nicotine dependence. Other receptor subtypes mediate the effects of nicotine on attention, anxiety, appetite, and arousal.
Nicotine itself is a small lipid-soluble molecule that crosses the blood-brain barrier within ten to twenty seconds of inhalation. The plasma half-life is approximately two hours, and metabolism is primarily by cytochrome P450 2A6 in the liver, producing the inactive metabolite cotinine that is widely used as a biomarker of nicotine exposure. The short half-life means that a regular smoker who is not currently smoking is in mild withdrawal within an hour or two of the last cigarette, which drives the regular short-interval dosing pattern that defines smoking. Patients trying to stop smoking by cutting back to a few cigarettes per day generally fail because the few they still smoke maintain the receptor sensitisation while doing nothing to address the underlying dependence.
| Parameter | Value | Clinical implication |
|---|---|---|
| Onset (inhaled) | 10 to 20 seconds | Strong reinforcement; explains addictive potential |
| Plasma half-life | Approximately 2 hours | Drives frequent dosing pattern in daily smokers |
| Cotinine half-life | 16 to 19 hours | Used as biomarker of nicotine exposure |
| Metabolism | CYP2A6 | Varies by genotype; slow metabolisers smoke less |
| Receptor | Alpha-4-beta-2 nicotinic acetylcholine receptor | Target of varenicline; key to dependence and to treatment |
Tobacco products, vaping, and nicotine pouches
Nicotine is delivered through several types of products. Combustible tobacco includes cigarettes, cigars, pipes, and shisha pipes, and delivers nicotine alongside thousands of combustion by-products including tar, carbon monoxide, and dozens of identified carcinogens. The combustion products are responsible for most of the disease burden of smoking. Smokeless tobacco products including chewing tobacco, snus, and dipping tobacco deliver nicotine through oral absorption without combustion, and produce a different but still significant disease burden including oral cancer, dental disease, and cardiovascular harm. Vaping products including refillable vape pens and pre-filled pod systems deliver nicotine as an aerosol generated by heating a propylene glycol or glycerol liquid containing nicotine and flavourings. Vaping avoids most of the combustion products of cigarettes but is not risk-free; the long-term respiratory and cardiovascular effects of vaping are still emerging, and the high nicotine concentrations in some pod systems produce intense dependence in young users who would not have started on cigarettes.
Nicotine pouches, a more recent category, deliver nicotine through oral absorption from small pouches placed between gum and lip. These products contain no tobacco; the nicotine is pharmaceutical-grade or synthesised. Brand names including Zyn, Velo, and On are widely marketed as smoking and vaping alternatives. The dependence pattern with pouches is similar to that with smokeless tobacco: less acute pleasure than inhaled products, but reliable steady-state nicotine levels and rapid development of dependence in regular users. Heated tobacco products, sometimes called IQOS-style products, heat tobacco without burning it and produce an aerosol that delivers nicotine with fewer combustion products than cigarettes but more than vaping. The disease profile of these newer products is still being characterised, and the dependence profile is essentially the same as for other nicotine delivery methods.
Nicotine withdrawal symptoms
Nicotine withdrawal begins within hours of the last nicotine exposure in regular users. The early symptoms include irritability, anxiety, restlessness, difficulty concentrating, low mood, increased appetite, sleep disruption, and intense cravings to use nicotine. Physical symptoms include slowed heart rate, mild blood pressure changes, headache, and gastrointestinal symptoms. The symptoms peak in intensity around the second to fourth day after stopping and then decline gradually over the following two to four weeks, although cravings can persist for months and increased appetite often lasts for six months or longer.
Withdrawal symptoms are real, measurable, and a major reason that most quit attempts fail in the first week. Patients who are aware of the timeline find it easier to push through the worst of the symptoms, particularly if they have a structured plan that includes nicotine replacement therapy, varenicline, or bupropion alongside behavioural support. Patients who attempt to stop cold turkey, without medication and without behavioural support, have a quit rate of around three to five percent at six months. With combined pharmacotherapy and structured behavioural support, the six-month quit rate rises to twenty to thirty percent.
| Symptom | Onset | Duration |
|---|---|---|
| Cravings | Within hours | Most intense first 1 to 2 weeks; can persist months |
| Irritability and anxiety | First 24 hours | Peak days 2 to 4; resolves over 2 to 4 weeks |
| Low mood | Day 1 to 3 | Resolves over 2 to 6 weeks |
| Difficulty concentrating | Day 1 to 3 | Resolves over 1 to 4 weeks |
| Increased appetite and weight | Within days | Often persists 6 months or longer |
Health effects of smoking and vaping
The health effects of smoking are exceptionally well documented and include lung cancer, head and neck cancer, oesophageal cancer, bladder cancer, kidney cancer, pancreatic cancer, cervical cancer, and acute myeloid leukaemia. Smoking causes chronic obstructive pulmonary disease, accounting for the majority of cases globally, and worsens asthma. Smoking is a major cause of cardiovascular disease, including coronary artery disease, stroke, peripheral arterial disease, and aortic aneurysm, and contributes to the increased thrombotic risk in women on combined hormonal contraception over the age of 35. Smoking causes infertility in both sexes, raises the risk of miscarriage and stillbirth, and is linked to reduced birth weight and increased perinatal complications. The cumulative life expectancy reduction of lifelong smoking is approximately ten years, and quitting smoking at any age produces measurable health benefits.
The health effects of vaping are less well characterised because the products are relatively new, but the picture is emerging. Acute respiratory effects of high-intensity vaping are documented, including the e-cigarette and vaping-associated lung injury cluster reported in the United States in 2019, mostly associated with adulterated cannabis vape liquids. Chronic respiratory effects of nicotine vaping include cough, chest tightness, and reduced exercise capacity in heavy users. Cardiovascular effects of vaping are measurable in laboratory studies including endothelial dysfunction and platelet activation. The cancer risk of vaping appears to be substantially lower than that of smoking, but the absolute risk is not zero, and the long-term effects of decades of vaping are not yet known.
Nicotine itself, separate from the delivery vehicle, has cardiovascular effects including raised heart rate, raised blood pressure, vasoconstriction, and platelet activation. These effects are mild compared with the effects of cigarette smoke but are not zero. Nicotine is also implicated in adverse brain development effects in adolescents and young adults, with the prefrontal cortex still developing into the mid-twenties and vulnerable to disruption by chronic nicotine exposure. This is part of why nicotine pouches and high-strength vape products marketed to young users raise particular public health concern.
Mental health, nicotine, and substance use disorders
Nicotine dependence is over-represented in patients with mental health conditions and with other substance use disorders. Roughly two-thirds of patients with serious mental illness smoke, against around fifteen percent in the general population in most developed countries. Patients with alcohol use disorder smoke at three to four times the rate of the general population, and the two dependences interact: nicotine and alcohol use share neural pathways, both drive dopamine release, and both are reinforced by social and contextual cues. Quitting smoking does not worsen depression or anxiety on average, contrary to long-standing folk belief; in most patients, quitting actually improves mood and anxiety scores over months.
The clinical implication is that nicotine treatment should be offered alongside treatment for any other substance use disorder or mental health condition, rather than deferred until the rest of the picture is stable. Many patients in early recovery from alcohol or drug use disorder continue to smoke at high rates and explain that they will address the smoking later. The evidence is that addressing the smoking during or shortly after the other recovery work produces better outcomes for both, partly because the smoking itself is a relapse trigger for the original substance and partly because the recovery infrastructure is in place to support a serious nicotine quit attempt.
Treatment for nicotine addiction at Phuket Island Rehab
Treatment for nicotine dependence at our clinic is built on the same evidence base that informs the major international guidelines, including those from the United States Public Health Service, the UK National Institute for Health and Care Excellence, and the World Health Organization. The pharmacotherapy options include nicotine replacement therapy in several forms including patches, gum, lozenges, inhalers, and nasal spray; varenicline, a partial agonist at the alpha-4-beta-2 nicotinic acetylcholine receptor that reduces cravings and blunts the reinforcing effect of any cigarette the patient does smoke; and bupropion, an antidepressant that has dopaminergic effects helpful in nicotine cessation. Combination therapy, often nicotine patch with a short-acting nicotine product or varenicline with nicotine replacement, is more effective than any single agent.
Behavioural support runs alongside the medication. Patients work with our counsellors on the triggers and cues that drive their smoking, on the social and contextual factors that reinforce the habit, on stress management strategies that do not depend on nicotine, and on the connection between their smoking and their other substance use. Group therapy, individual sessions, and structured cessation modules form the backbone of the behavioural component. For patients with co-occurring alcohol use disorder, the nicotine and the alcohol are typically addressed together rather than in sequence. For patients with co-occurring mental health conditions, the nicotine treatment is integrated with the mental health work so that the cessation does not destabilise other recovery.
The residential setting matters for nicotine treatment because it allows continuous behavioural support through the first one to two weeks of quit, which is when most quit attempts fail. The setting also removes the patient from the smoking cues that dominate the home and work environments, gives time for the neural adaptation to begin, and provides the structure that makes the medication and behavioural plan stick. Patients who leave residential treatment having stopped smoking, with a plan for ongoing pharmacotherapy and behavioural support, have a measurably higher one-year quit rate than patients in outpatient programmes.
Why international clients come to Thailand
Patients from the United States, the United Kingdom, Australia, and continental Europe travel to Phuket Island Rehab for treatment of complex addiction pictures that almost always include nicotine dependence alongside alcohol or other substance use. The first reason is the residential continuum of care: patients arrive, receive a structured medical detox if needed, transition into residential rehab with parallel nicotine and substance treatment, step down through partial hospitalisation or intensive outpatient services as appropriate, and leave with a written aftercare plan. The second is privacy: many patients prefer to address their full substance picture, including the smoking that often feels embarrassing in the context of other addictions, away from their domestic environment.
The third is the difference the Phuket setting makes to the early recovery experience. The climate supports outdoor exercise, the food is excellent, the pace of life on the island is gentler than most domestic rehab settings, and the visual and sensory environment is far removed from the smoking cues of the patient’s normal life. The cost of a full residential programme in Phuket, including medical detox, therapy, accommodation, food, and excursions, is a fraction of the equivalent domestic programme, which often allows a longer stay and a fuller recovery arc that includes meaningful nicotine work rather than treating the smoking as an afterthought.
When smoking or vaping has become more than occasional
Many of the people who reach out to our team are not in obvious nicotine crisis. They are still working, still functioning. They may smoke ten to twenty cigarettes a day, vape constantly from a pod device, or use several nicotine pouches per day, and they have come to accept the dependence as part of their life. What has often changed is that the underlying health, the dental work, the respiratory function, or the cardiovascular checks are showing the cumulative effect, or the patient is increasingly aware that the nicotine is interacting with their drinking, their anxiety, or their depression in ways they no longer want. If you are looking for treatment for nicotine dependence, the next step is a conversation with a clinician who treats nicotine as a serious dependence in its own right rather than as a lifestyle issue.
Heavy drinking alongside nicotine use is the single most common comorbidity in this group. The two dependences share neural pathways, both drive dopamine release, and the contextual link between drinking and smoking is one of the most robust findings in addiction research. Patients with alcohol use disorder who treat the alcohol but continue to smoke have a higher relapse rate at one year than patients who address both. Any honest treatment plan asks about the smoking pattern from the first interview and treats the nicotine as part of the same problem.
Summary
Nicotine addiction is a serious chronic dependence that affects more than a billion people globally and remains one of the leading preventable causes of disease and premature death. The drug acts at nicotinic acetylcholine receptors, drives dopamine release in the reward system, and produces a recognisable pattern of compulsive use that resists casual attempts to stop. Withdrawal symptoms including irritability, anxiety, low mood, cravings, sleep disruption, and increased appetite are real and account for most of the failed quit attempts in the first week. Evidence-based treatment combines pharmacotherapy with nicotine replacement, varenicline, or bupropion with structured behavioural support, ideally in a setting that interrupts daily smoking cues. A residential setting, parallel treatment of any co-occurring alcohol use disorder or other substance use, and a clear aftercare plan are the components of a recovery that lasts beyond the early weeks.
As our counsellor Dr. Ponlawat Pitsuwan puts it, “Nicotine is the dependence most patients say they will deal with later, and it is the dependence most likely to bring them back if it is not addressed. We treat smoking as part of the addiction picture, not as a separate problem. The patients who leave us without their cigarettes do better with the rest of their recovery, and they tend to feel better about themselves in ways they did not expect.”
Frequently asked questions about nicotine addiction
Is nicotine addictive?
Yes. Nicotine is one of the most addictive substances in common use. The drug acts on nicotinic acetylcholine receptors in the brain, drives dopamine release in the reward system, and produces both physical dependence and a behavioural pattern of compulsive use. Most daily smokers meet criteria for tobacco use disorder within months of starting regular smoking. The dependence is reinforced by frequent dosing through the day, by the rapid delivery of nicotine to the brain via inhaled smoke or vapour, and by the integration of smoking into daily routines and social cues.
What are common nicotine withdrawal symptoms?
Common withdrawal symptoms include irritability, anxiety, restlessness, difficulty concentrating, low mood, increased appetite, sleep disruption, and intense cravings to smoke or vape. Physical symptoms include slowed heart rate, mild blood pressure changes, headache, and gastrointestinal symptoms. The symptoms peak around the second to fourth day after stopping and decline over two to four weeks, although cravings and increased appetite often persist for months. Symptoms are real and measurable, and a structured quit plan that includes pharmacotherapy and behavioural support makes the symptoms substantially easier to manage.
Is vaping safer than smoking?
Vaping is generally considered safer than smoking but is not risk-free. Vaping avoids most of the combustion products that drive cigarette-related cancer and respiratory disease, and is associated with lower acute respiratory effects than cigarette smoking. However, vaping still delivers nicotine, with all the cardiovascular effects of nicotine, and the long-term respiratory and cardiovascular effects of decades of vaping are not yet known. For an established smoker, switching completely to vaping is likely safer than continuing to smoke; for a non-smoker, taking up vaping is not safer than not vaping at all.
How long does nicotine stay in your system?
Nicotine itself has a plasma half-life of approximately two hours and is generally cleared from the bloodstream within 24 hours of the last exposure. The main metabolite, cotinine, has a half-life of 16 to 19 hours and is detectable in urine for one to four days after the last nicotine exposure, longer in heavy smokers. Cotinine is commonly used as a biomarker of nicotine exposure in clinical and research settings. Some products and laboratories use other markers, but cotinine is the most widely used. Hair testing can detect chronic nicotine exposure for three months or longer.
What is the best way to quit smoking?
The most effective approach combines pharmacotherapy with structured behavioural support. Pharmacotherapy options include nicotine replacement therapy in several forms including patches, gum, lozenges, inhalers, and nasal spray; varenicline, a partial agonist at the nicotinic acetylcholine receptor; and bupropion, an antidepressant with dopaminergic effects. Combination therapy is more effective than any single agent. Behavioural support includes individual counselling, group therapy, structured cessation modules, and brief interventions from primary care. The six-month quit rate with combined pharmacotherapy and behavioural support is twenty to thirty percent, compared with three to five percent for unsupported attempts. Treatment in a residential setting that interrupts daily smoking cues improves quit rates further.
Can you treat nicotine and alcohol addiction together?
Yes, and treating both together is more effective than treating one and then the other. Nicotine and alcohol dependences share neural pathways, are linked by contextual cues, and reinforce each other in daily life. Patients who treat their alcohol use disorder but continue to smoke have a higher relapse rate at one year. Patients who address both during the same treatment episode generally do better with both. Residential treatment is well placed to provide this combined approach because it interrupts both sets of cues and provides the medical and behavioural infrastructure for both.
Sources
World Health Organization. Tobacco fact sheet. https://www.who.int/news-room/fact-sheets/detail/tobacco
Centers for Disease Control and Prevention. Smoking and Tobacco Use. https://www.cdc.gov/tobacco/
United States Surgeon General. The Health Consequences of Smoking — 50 Years of Progress. https://www.cdc.gov/tobacco/sgr/50th-anniversary/index.htm
National Institute on Drug Abuse (NIDA). Tobacco, Nicotine, and E-Cigarettes. https://nida.nih.gov/research-topics/tobacco-nicotine-e-cigarettes
National Institute for Health and Care Excellence (NICE). Tobacco: preventing uptake, promoting quitting and treating dependence. https://www.nice.org.uk/guidance/ng209
Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. https://www.cochranelibrary.com
Substance Abuse and Mental Health Services Administration (SAMHSA). Treating tobacco use and dependence in behavioral health settings. https://www.samhsa.gov
Nicotine dependence: clinical detail and risk profile
Tobacco and nicotine products including cigarettes, cigars, vape devices, and pouches deliver nicotine to the brain over seconds, drive dopamine in the reward system, and produce both physical and behavioral dependence. Common symptoms of nicotine withdrawal include irritability, anxiety, low mood, sleep disturbance, increased appetite, and intense cravings, and the symptoms typically peak in the first week. Effects of long-term smoking include lung disease, cardiovascular disease, and increased cancer risk; effects of vaping appear lower than smoking but are not zero. Help with stopping is most effective when pharmacotherapy is combined with structured behavioral support. People who use nicotine products daily are usually physically dependent, even if they do not feel addicted in the way they might with alcohol or other drugs. The time required for the dependence to settle after stopping varies, but most physical symptoms ease over weeks, while cravings can persist for months. Nicotine gum, patches, lozenges, varenicline, and bupropion are all common treatments. Including treatment of nicotine use as part of a wider substance use treatment plan, particularly alongside alcohol use disorder, generally produces better outcomes for both.
Nicotine addiction — key entities and related terms
Nicotine, nicotinic acetylcholine receptor, alpha-4-beta-2 receptor, dopamine, ventral tegmental area, nucleus accumbens, tobacco, cigarettes, cigars, pipe tobacco, shisha, smokeless tobacco, chewing tobacco, snus, vaping, e-cigarettes, vape pen, pod system, propylene glycol, glycerol, nicotine pouch, Zyn, Velo, On, heated tobacco, IQOS, cotinine, CYP2A6, plasma half-life, tobacco use disorder, DSM-5, ICD-11, nicotine withdrawal, irritability, anxiety, cravings, low mood, sleep disruption, increased appetite, lung cancer, COPD, cardiovascular disease, stroke, peripheral arterial disease, perinatal effects, EVALI, e-cigarette and vaping-associated lung injury, nicotine replacement therapy, NRT, nicotine patch, nicotine gum, lozenge, inhaler, nasal spray, varenicline, bupropion, alcohol use disorder, AUD, dual diagnosis, residential rehab, behavioural support, Phuket Island Rehab, Dr. Ponlawat Pitsuwan, Dr. Ponlawat Pitsuwan, WHO, CDC, US Surgeon General, NIDA, NICE, SAMHSA, Cochrane.